All In Biotech

Drug Trial Radar · NCT06970106

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

A Phase 1b Open-Label, Randomized, Single Dose and Repeat Dose Study to Evaluate the Single and Repeat Dose Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Oct 2029

Study completion Nov 2029

Sponsor

Lead sponsor
PYC TherapeuticsIndustry
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approximately 18 participants from Australia, New Zealand, and other APAC countries are expected to be enrolled, depending on safety review committee (SRC) throughout the course of the study. Participants may be assigned to any of the following: 1. A single 60ug dose of PYC-001 2. Three doses of 10ug PYC-001 at an interval of 8 weeks 3. Three doses of 10ug PYC-001 at an interval of 12 weeks 4. Three doses of 30ug PYC-001 at an interval of 8 weeks 5. Three doses of 30ug PYC-001 at an interval of 12 weeks Following completion of the 4 week safety review of the single 60ug of PYC-001 cohort, and if the 60 μg dose level is deemed safe by the SRC, the following cohorts will also be available: 6. Three doses of 60ug PYC-001 at an interval of 12 weeks

Conditions

  • OPA1 Gene Mutation
  • Autosomal Dominant Optic Atrophy
  • Hereditary Optic Atrophies
  • Kjer Optic Atrophy

Interventions

  • PYC-001Drug

    PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [All Cohorts] Number of participants experiencing treatment emergent adverse eventsTime frame: Up to 164 weeks
  2. [All Cohorts] Changes from baseline in vital signs (heart rate)Time frame: Up to 164 weeks
  3. [All Cohorts] Changes from baseline in vital signs (systolic and diastolic blood pressure)Time frame: Up to 164 weeks
  4. [All Cohorts] Changes from baseline in vital signs (tympanic temperature)Time frame: Up to 164 weeks
  5. [All Cohorts] Changes from baseline in vital signs (respiratory rate)Time frame: Up to 164 weeks
  6. [All Cohorts] Change from baseline in white blood cells (WBC), platelets, white blood cell count with differential neutrophil count, eosinophil count, basophil count, lymphocyte count, monocyte countTime frame: Up to 164 weeks
  7. [All Cohorts] Change from baseline in red blood cellsTime frame: Up to 164 weeks
  8. [All Cohorts] Change from baseline in hemoglobin and mean corpuscular hemaglobin concentrationTime frame: Up to164 weeks
  9. [All Cohorts] Change from baseline in mean corpuscular volume and mean platelet volumeTime frame: Up to 164 weeks
  10. [All Cohorts] Change from baseline in hematocritTime frame: Up to 164 weeks
  11. [All Cohorts] Change from baseline in mean corpuscular hemoglobinTime frame: Up to 164 weeks
  12. [All Cohorts] Change from baseline in neutrophils, lymphocytes, monocytes, eosinophils, basophils and reticulocyte countTime frame: Up to 164 weeks
  13. [All Cohorts] Change from baseline in Alanine Transaminase, Alkaline Phosphatase, Aspartate aminotransferase, Creatine Phosphokinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase, Amylase and LipaseTime frame: Up to 164 weeks
  14. [All Cohorts] Change from baseline in Bilirubin (total, direct and indirect) and creatinineTime frame: Up to 164 weeks
  15. [All Cohorts] Change from baseline in protein, albumin, globulin and fibrinogenTime frame: Up to 164 weeks
  16. [All Cohorts] Change from baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphorous, Total Cholesterol, Triglyceride, HDL, LD. Uric Acid and GlucoseTime frame: Up to 164 weeks
  17. [All Cohorts] Change from baseline in Anion GapTime frame: Up to 164 weeks
  18. [All Cohorts] Change from baseline in Estimated Glomerular Filtration Rate (eGFR)Time frame: Up to 164 weeks
  19. [All Cohorts] Change from baseline in Prothrombin Time and Partial Thromboplastin Time, Activated (APTT)Time frame: Up to 164 weeks
  20. [All Cohorts] Change from baseline in Prothrombin Time (INR)Time frame: Up to 164 weeks
  21. [All Cohorts] Change from baseline in urinalysis (Protein, glucose, ketones, blood, bilirubin, leucocyte esterase and nitritesTime frame: Up to 164 weeks
  22. [All Cohorts] Change from baseline in urinalysis (pH)Time frame: Up to 164 weeks
  23. [All Cohorts] Change from baseline in urinalysis (specific gravity)Time frame: Up to 164 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Cerulea Clinical Trials

    East Melbourne, Australia · Recruiting

  • Save Sight Institute - Sydney Eye Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Retina Specialists

    Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.